Physician

Paul Getz, MD

According to 2025 Medicare claims, Paul Getz, MD (NPI: 1508866443) practices dermatology in the Elgin, IL market, with the plurality of this provider's patient population coming from Kane, IL. This provider's primary affiliated billing organization is PAUL GETZ, M.D., S.C. (NPI: 1740302165; TIN: 364316574) and primary practice location at 60118-3330.

Getz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 910 traditional Medicare patients, billed 5,162 HCPCS/CPT codes, and received $403,610 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,929 prescription claims across 773 beneficiaries totaling $795,270 in drug costs, led by Bimzelx (Bimekizumab-Bkzx). Open Payments data shows 197 records totaling $597,025. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $288,927 to $403,610. Similarly, Part D prescription costs have risen steadily, from $422,040 to $795,270. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$243K$486K2015 Medicare payment: $288,927 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $281,178 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $263,252 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $304,823 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $250,805 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $202,154 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $308,731 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $485,979 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $421,653 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $403,610 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,3235,146$288,927
20161,2594,955$281,178
20171,1994,572$263,252
20181,2068,636$304,823
20191,0495,627$250,805
20208405,325$202,154
20219287,616$308,731
20229225,987$485,979
20239695,312$421,653
20249105,162$403,610

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$398K$795K2015 Drug cost: $422,040 (USD; Tot_Drug_Cst)2016 Drug cost: $335,290 (USD; Tot_Drug_Cst)2017 Drug cost: $385,913 (USD; Tot_Drug_Cst)2018 Drug cost: $468,697 (USD; Tot_Drug_Cst)2019 Drug cost: $365,406 (USD; Tot_Drug_Cst)2020 Drug cost: $436,219 (USD; Tot_Drug_Cst)2021 Drug cost: $395,530 (USD; Tot_Drug_Cst)2022 Drug cost: $356,359 (USD; Tot_Drug_Cst)2023 Drug cost: $611,933 (USD; Tot_Drug_Cst)2024 Drug cost: $795,270 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20154681,190$422,040
20165271,294$335,290
20175571,435$385,913
20185981,406$468,697
20195221,243$365,406
20205171,289$436,219
20215441,446$395,530
20225211,329$356,359
20235711,553$611,933
20247731,929$795,270

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths187216$78
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more190190$71
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more615857$62
17000Destruction of precancer skin growth, 1 growth152185$40
17003Destruction of precancer skin growth, 2-14 growths103503$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
BimzelxBimekizumab-Bkzx11420$198,030
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc3178,587$6,508
Ammonium LactateAmmonium Lactate2498,429$5,549
TacrolimusTacrolimus481,265$5,473
KetoconazoleKetoconazole2517,554$4,078

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.43$985ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.154$596,040Novartis Pharmaceuticals Corporation
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Paul Getz, MD?

Tedicare shows public-source Medicare data for Paul Getz, MD (NPI 1508866443), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul Getz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Paul Getz, MD?

Paul Getz, MD is linked to PAUL GETZ, M.D., S.C. (billing NPI 1740302165) in the available physician profile data.

Does Paul Getz, MD have Open Payments data?

Paul Getz, MD has 197 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.